within Pharmacolibrary.Drugs.ATC.C;

model C02AC05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.88,
    Cl             = 0.0021666666666666666,
    adminDuration  = 600,
    adminMass      = 0.2 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02AC05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Moxonidine is an antihypertensive agent, acting as an imidazoline receptor agonist, predominantly used to treat mild to moderate essential hypertension. It reduces sympathetic nervous system activity, leading to vasodilation and lowered blood pressure. Moxonidine is approved and in clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Reported pharmacokinetic parameters in healthy adult volunteers, mostly men and women, aged 18-65, after single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Kirch, W, et al., &amp; Plänitz, V (1990). Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertension patients. <i>Journal of clinical pharmacology</i> 30(12) 1088–1095. DOI:<a href=&quot;https://doi.org/10.1002/j.1552-4604.1990.tb01850.x&quot;>10.1002/j.1552-4604.1990.tb01850.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2273081/&quot;>https://pubmed.ncbi.nlm.nih.gov/2273081</a></p></li><li><p>Prichard, BN (1994). Clinical experience with moxonidine. <i>Cardiovascular drugs and therapy</i> 8 Suppl 1 49–58. DOI:<a href=&quot;https://doi.org/10.1007/BF00877084&quot;>10.1007/BF00877084</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8068579/&quot;>https://pubmed.ncbi.nlm.nih.gov/8068579</a></p></li><li><p>Kirch, W, et al., &amp; Plänitz, V (1988). The influence of renal function on clinical pharmacokinetics of moxonidine. <i>Clinical pharmacokinetics</i> 15(4) 245–253. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198815040-00004&quot;>10.2165/00003088-198815040-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3191647/&quot;>https://pubmed.ncbi.nlm.nih.gov/3191647</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02AC05;
